ALUMIS INC.
Alumis is a clinical-stage biopharmaceutical company developing targeted therapies for immune-mediated diseases. Its main programs are envudeucitinib, or envu, an allosteric TYK2 inhibitor being studied for plaque psoriasis and systemic lupus erythematosus, and A-005, a central nervous system-penetrant TYK2 inhibitor being evaluated for potential use in neurological and other diseases. Alumis also has lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R for thyroid eye disease, and earlier-stage discovery programs including IRF5. Alumis uses a proprietary precision data analytics platform and drug discovery expertise to identify targets and develop product candidates. It has not established a full commercial organization or distribution capabilities. The company relies on third parties to manufacture its candidates for clinical testing and any potential commercial use. Alumis is headquartered in South San Francisco, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Wells Fargo downgraded its price target for Alumis to $18 from $25, a 28% decrease, while maintaining an Overweight rating. The new target implies a 193.6% upside from the Nov 12 close of $6.13, according to the bank.
HC Wainwright & Co. kept its Buy rating on Alumis but reduced its price target from $15 to $9, a 40% drop. This implies a 46.8% upside from the Nov 12 close of $6.13.
Alumis reported 3Q 2026 revenue of $1.91M, down 8% YoY, with a net loss of $94.88M, improved 14% YoY. R&D expenses fell 17% due to completed trials. The company plans an NDA submission for envu in psoriasis by year-end and is exploring strategic alternatives for lonigutamab.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning ALMS (ALUMIS INC.). Coverage has skewed bearish: 2 bullish, 0 neutral, and 3 bearish.
Recent ALMS coverage spans financial news, earnings and market movers.
In the last 30 days, ALMS insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($24K). The most active reporter was Pangali Sanam, Chief Legal Officer, with 1 filing.
Wells Fargo downgraded its price target for Alumis to $18 from $25, a 28% decrease, while maintaining an Overweight rating. The new target implies a 193.6% upside from the Nov 12 close of $6.13, according to the bank.
HC Wainwright & Co. kept its Buy rating on Alumis but reduced its price target from $15 to $9, a 40% drop. This implies a 46.8% upside from the Nov 12 close of $6.13.
Positive Phase 2b data and reduced R&D spend may improve outlook.
The sizable net loss and cash runway update may pressure the stock as investors reassess burn rate.
The missed SLE trial results introduce clinical risk, while the solid psoriasis data and cash runway provide some upside.
AlphAI scores every news story that mentions ALMS with an AI model for sentiment and relevance, and aggregates insider trades from ALUMIS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Wells Fargo downgraded its price target for Alumis to $18 from $25, a 28% decrease, while maintaining an Overweight rating. The new target implies a 193.6% upside from the Nov 12 close of $6.13, according to the bank.
HC Wainwright & Co. kept its Buy rating on Alumis but reduced its price target from $15 to $9, a 40% drop. This implies a 46.8% upside from the Nov 12 close of $6.13.
Alumis reported 3Q 2026 revenue of $1.91M, down 8% YoY, with a net loss of $94.88M, improved 14% YoY. R&D expenses fell 17% due to completed trials. The company plans an NDA submission for envu in psoriasis by year-end and is exploring strategic alternatives for lonigutamab.
Alumis reported Q3 2026 revenue of $1.9M and a net loss of $94.9M. Cash reserves totaled $431.3M, expected to last into Q4 2027. The company plans to submit an NDA for envudeucitinib in plaque psoriasis by Q4 2026, with positive Phase 3 data for scalp psoriasis. A Phase 2b trial in lupus did not meet primary endpoints, but a subgroup showed responses. Alumis will start a Phase 2 trial for A-005 in Parkinson's in 2027.
ALUMIS INC. (ALMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates – New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib’s differentiated clinical profile, including the hig
Voya MI Dynamic Small Cap Fund reported that its overweight position in Alumis (ALMS) hurt performance due to disappointing clinical trial results. ALMS closed at $6.62 with a $883.74M market cap, up 25.38% over 52 weeks. The fund's Q3 2026 letter cited sector performance variations, with energy, tech, and healthcare outperforming.
Alumis Inc. (ALMS) reported positive Phase 3 data for envudeucitinib, showing 54% PASI 100 response at Week 48. The therapy improved scalp clearance, itch relief, and quality of life. Alumis plans to submit an NDA in 4Q 2026. The treatment was well-tolerated with no new safety signals.
H.C. Wainwright reiterated a Buy rating and $15.00 price target on Alumis Inc (ALMS) after positive LATITUDE Atlas trial results for zaso. The stock trades at $6.85, down from its 52-week high. Analysts view the data favorably but note mixed reactions due to recent Phase 2b trial failures for Envudeucitinib.
On September 9, 2026, significant insider trading activity was reported. Alumis Inc. (ALMS) director acquired $10.7M in shares, while NVIDIA (NVDA) director sold $235.6M. Greenwave (GWAV) CEO bought $8M in shares, and BELITE BIO (BLTE) executives sold $31.9M. Workday (WDAY) director sold $17.9M in shares. Dell (DELL) insiders sold $48.1M. Inhibrx (INBX) and Cytosorbents (CTSO) directors also made notable purchases.
Alumis (ALMS) stock rose 6.3% in pre-market trading after presenting long-term skin-clearance data for envudeucitinib at the Cantor Fitzgerald Global Healthcare Conference. Management highlighted potential partnerships and insider Srinivas Akkaraju bought 986,000 shares. The FDA application for envudeucitinib is expected in Q4 2026.
